Resectable Non-Small Cell Lung Cancer

Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.

A recent analysis of global conversations involving almost 1,500 health care professionals on social media from Oct. 1 to 31 has revealed a predominantly positive reaction to the FDA’s approval of Novavax’s updated COVID-19 vaccine.